Despite the efficacy of PD-1/PD-L1 inhibitors in cancer therapy, several molecular targeted drugs have been implicated in the development of renal complications, which can range from distinct renal irAEs to extrarenal irAEs. This evidence concerns the gene CD274 and cancer.